Aqualung Therapeutics

company

About

Aqualung Therapeutics is developing a novel, anti-inflammatory monoclonal antibody strategy to treat serious unchecked inflammation.

  • 1 - 10

Details

Last Funding Type
Grant
Last Funding Money Raised
$2.30M
Industries
Biotechnology,Medical
Founded date
Jan 1, 2010
Number Of Employee
1 - 10
Operating Status
Active

Aqualung Therapeutics (Aqualung Therapeutics Corporation) leadership are experienced academic leaders, entrepreneurs and translational scientists with expertise in Precision Medicine, who are exploring NAMPT as a key target and novel diagnostic in acute and chronic lung inflammatory disorders. As an organization they are committed to finding novel targets in the treatment of respiratory diseases. Their team is highly skilled at clinical development and they are working collaboratively with the FDA to ensure both acute and chronic respiratory diseases that have significant unmet medical need receive priority review.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$2.82M
Aqualung Therapeutics has raised a total of $2.82M in funding over 2 rounds. Their latest funding was raised on Sep 22, 2020 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 22, 2020 Grant $300K 1 National Institutes of Health Detail
Jun 2, 2020 Grant $2.30M 1 National Institutes of Health Detail
Aug 20, 2019 Grant $225K 1 National Institutes of Health Detail

Investors

Number of Lead Investors
Number of Investors
3
1
Aqualung Therapeutics is funded by 1 investors. National Institutes of Health are the most recent investors.
Investor Name Lead Investor Funding Round
National Institutes of Health Yes Grant